

Onychomycosis of the Toenails: Pathophysiology, Epidemiology, Treatment Options and Setting Patient Treatment Expectations

PharmaDerm invites you to join your peers for an interactive presentation on the treatment of onychomycosis of the toenails. During the presentation you will have the opportunity to engage in discussion around treatment options, including KERYDIN® (tavaborole) Topical Solution, 5%, the first and only boron-based antifungal for the treatment of onychomycosis of the toenails. Additionally, discussion will highlight ways to engage with patients to raise awareness of onychomycosis of the toenails as well as how to set patient expectations for treatment. A modest meal may be provided (may be subject to reporting under the Sunshine Act).

SPEAKER

Warren S. Joseph, DPM, FIDSA

Consultant, Lower Extremity Infectious Diseases
Roxborough Memorial Hospital
Philadelphia, PA

DATE AND TIME

Tuesday, February 9, 2015

6:30PM - 8:30PM

LOCATION

Restaurant X

117 North Route 303

Congers, NY 10920

Register today by phone or online!

Phone: (877) 796-4882 <http://www.regonline.com/PharmaDermSB>*

Please register at least 3 days ahead of time, and RSVP early as space may be limited.
If you no longer wish to receive communications by fax please call toll-free (877) 796-4882.

*This meets img and privacy guidelines

Indication

KERYDIN® is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

Important Safety Information

KERYDIN® is for topical use only and not for oral, ophthalmic, or intravaginal use. The most commonly reported adverse events involved skin reactions in the application area, including exfoliation, ingrown toenail, erythema, and dermatitis.

Safety and effectiveness have not been evaluated or established in pregnant or breastfeeding women or pediatric patients. Please see provided full Prescribing Information.


Kerydin™
(TAVABOROLE)
TOPICAL SOLUTION, 5%

 **PharmaDerm®**
a division of Fougere Pharmaceuticals Inc.



Privacy Policy

Consent to Provide Your Information to Fougera

We request your permission to collect your personally identifiable information when you seek to register for a Fougera program or service. In doing so, we also explain the purpose for the collection of your personal information and how we plan to use it. We also offer you the option to discontinue your consent ("opting out" or "unsubscribing") if you later decide that you no longer want to participate in a program or service. If we wish to use this information for purposes other than those for which the data was initially collected, we will offer a means to opt out of the secondary use.

Sharing Your Information With Third-Parties

Fougera will not share your personal information with unaffiliated third-parties, such as marketers, for their own separate use unless we have obtained your opt-in consent to do so. When you provide personally identifiable information to Fougera, it will be accessible to some of Fougera's and Novartis' business partners, such as companies we retain to fulfill requests for information, or provide assistance to us on specific programs or projects. In those cases, the other companies may also have access to your personally identifiable information. Fougera requires third-parties to whom it discloses personal data to protect personal information using substantially similar standards to those required by Fougera. We also require that they not use your personal information for any separate use that is not specifically authorized by Fougera.

There may also be instances where Fougera may be required to share your information with third-parties who have not been retained by us (directly or indirectly), for example, if we are required to do so because of an applicable law, court order or governmental regulation, or if such disclosure is otherwise necessary in support of any criminal or other legal investigation or proceeding here or abroad. Many entities receiving personally identifiable information under these conditions have privacy requirements that apply to their handling of your information.

Personal Information collected from you may also be transferred to a third party in the event that the business of this site or a part of it and the customer data connected with it is sold, assigned or transferred, in which case we would require the buyer, assignee or transferee to treat your information in accordance with this Privacy Statement.

How to Contact Us

If you have any questions about our Privacy Policy, please write to us at Fougera Pharmaceuticals Inc., Attention Data Privacy Officer, 60 Baylis Road, Melville, NY 11747, or via e-mail at data.privacy@sandoz.com.

The Sunshine Act

Under the Physician Payment Sunshine Act (Section 6002 of the Patient Protection and Affordable Care Act), medical device, biologic, and drug manufacturers are required to track and report all payments and transfers of value (TOV) to U.S. physicians and doctors of osteopathy (covered recipients) made on or after August 1, 2013. Covered recipients include: MD, DO, DDS, DMD, DPM, OD, and DC. As defined by the Sunshine Act, TOV include, but are not limited to, gifts, food and beverages, entertainment, consulting fees, and honoraria.

PharmaDerm is compliant with the Physician Payment Sunshine Act reporting requirements. As such, the National Provider Identifier (NPI) number, a unique identification number assigned to each U.S. healthcare provider will be used, along with state license numbers, to record and track these transactions. All attendees speaking at or participating in this event must supply their NPI number and state license number(s), if applicable.

Indication

KERYDIN® is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

Important Safety Information

KERYDIN® is for topical use only and not for oral, ophthalmic, or intravaginal use. The most commonly reported adverse events involved skin reactions in the application area, including exfoliation, ingrown toenail, erythema, and dermatitis.

Safety and effectiveness have not been evaluated or established in pregnant or breastfeeding women or pediatric patients. Please see provided full Prescribing Information.



Kerydin™
(TAVABOROLE)
TOPICAL SOLUTION, 5%

KERYDIN® is a trademark of Anacor Pharmaceuticals, Inc.
©2015 Fougera Pharmaceuticals Inc. All rights reserved.
98CPE110115

©2015 PharmaDerm



PharmaDerm®
a division of Fougera Pharmaceuticals Inc.